TGN-1062

TGN-1062 is a potent, selective, and reversible small molecule inhibitor of Cyclin-Dependent Kinase 7 (CDK7). Developed by The Translational Genomics Research Institute (TGen), it targets the catalytic ATP pocket of CDK7, which plays a critical role in both cell cycle regulation and transcriptional control. By inhibiting CDK7, TGN-1062 reduces the phosphorylation of RNA Polymerase II and suppresses the expression of oncogenic drivers like MYC. Preclinical studies have demonstrated its efficacy in pancreatic cancer models, particularly when combined with gemcitabine and nab-paclitaxel, as well as in acute myeloid leukemia (AML) and ovarian cancer models. The compound exhibits high oral bioavailability and a favorable safety profile in preliminary animal studies.